Autoimmune hepatitis in African Americans: presenting features and response to therapy

Area of Science:

• Hepatology
• Immunology
• Internal Medicine

Background:

• Autoimmune hepatitis (AIH) disproportionately affects African Americans, who often experience worse disease complications.
• Existing research on AIH predominantly features Caucasian populations, limiting understanding of disease characteristics in African Americans.
• Emory University's healthcare system serves a substantial African American demographic, including many with AIH, making it ideal for studying this population.

Purpose of the Study:

• To investigate potential differences in the clinical presentation and therapeutic response of autoimmune hepatitis between African Americans and white individuals.
• To compare the initial disease severity and treatment outcomes in African American and white patients diagnosed with autoimmune hepatitis.

Main Methods:

• A retrospective analysis was conducted at a tertiary referral center.
• The study included 27 African American patients and 24 white patients diagnosed with autoimmune hepatitis.
• Data collected included initial presenting features and response to therapy.

Main Results:

• African Americans were significantly more likely to have cirrhosis at initial diagnosis (85% vs. 38%).
• African Americans presented with more advanced disease, indicated by higher bilirubin levels and prolonged prothrombin times, though not statistically significant.
• Both groups showed good therapeutic response with reduced liver enzymes (AST, ALT) and bilirubin; biochemical remission rates were similar (50% African Americans vs. 48% whites).
• African Americans required a higher dosage of prednisone to maintain remission.

Conclusions:

• The majority of African Americans with autoimmune hepatitis present with cirrhosis, unlike white patients.
• Despite advanced initial presentation, African Americans demonstrate a favorable response to standard therapy.
• Long-term disease management in African Americans necessitates more intensive immunosuppression to achieve and maintain remission.